公开(公告)号：US11413255B2

公开(公告)日：2022-08-16

申请号：US15735214

申请日：2016-06-27

申请人： Montefiore Medical Center

发明人： Richard M. LoPachin ,  Terrence Gavin ,  Brian Geohagen

IPC分类号： A61K31/167 ,  A61K31/191 ,  A61K31/122 ,  A61K31/12 ,  C07C49/825 ,  C07C49/82 ,  C07C49/835 ,  C07C49/78 ,  C07C233/33 ,  C07C323/22 ,  A61K31/495 ,  A61K31/05 ,  A61K31/095 ,  A61K31/36 ,  A61P39/06 ,  A01N1/02 ,  A61K31/381 ,  A61K31/402 ,  A61K31/5375 ,  C07C49/80 ,  C07C49/807 ,  C07C49/84 ,  C07D207/04 ,  C07D207/325 ,  C07D295/112 ,  C07D333/22

摘要： Methods, filters and compositions are disclosed for treating toxicity due to oxidative stress and toxic electrophiles.

公开(公告)号：US20220135552A1

公开(公告)日：2022-05-05

申请号：US17453959

申请日：2021-11-08

申请人： SENTINEL ONCOLOGY LIMITED

发明人： Robert George BOYLE ,  David Winter WALKER ,  Richard Justin BOYCE

IPC分类号： C07D413/14 ,  A61P35/00 ,  C07D207/325 ,  C07D231/12 ,  C07D261/08 ,  C07D401/04 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D405/14 ,  C07D409/04 ,  C07D413/12

摘要： The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from various substituents: R2 is selected from hydrogen and a C1-4 hydrocarbon group; R3 is selected from hydrogen and a C1-4 hydrocarbon group; R4 is selected from various substituents; R5 is selected from various substituents; Ar2 is an optionally substituted phenyl, pyridyl or pyridone group; R6 is a group Q1-Ra—Rb; Q1 is absent or is a C1-3 saturated hydrocarbon linker; Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc; Rb is selected from hydrogen and various substituents; and Rb is selected from R4. The compounds are useful in the treatment of cancers.

公开(公告)号：US20200055820A1

公开(公告)日：2020-02-20

申请号：US16347069

申请日：2017-11-09

申请人： PIRELLI TYRE S.p.A ,  POLITECNICO DI MILANO

发明人： Maurizio Stefano GALIMBERTI ,  Vincenzina BARBERA

IPC分类号： C07D207/323 ,  C07D403/06 ,  C07F7/18 ,  C07D207/325 ,  C01B32/21 ,  C01B32/198

摘要： Adducts are described formed between pyrrole derivatives of formula (I) an carbon allotropes in which the carbon is sp2 hybridized, such as for example carbon nanotubes, graphene or nanographites, carbon black. The pyrrole derivatives bear substituents on the nitrogen atom suitable for improving the physicochemical characteristics of said allotropes. A process for preparing said adducts is also described. The adducts are formed with a pyrrole of formula (I) wherein X is selected from the group consisting of: The other substituents are as defined in the claims.

公开(公告)号：US10435363B2

公开(公告)日：2019-10-08

申请号：US15366229

申请日：2016-12-01

申请人： Cadila Healthcare Limited

发明人： Shriprakash Dhar Dwivedi ,  Ramesh Chandra Singh ,  Rajendra Gokalbhai Chavda ,  Jagdish Maganlal Patel ,  Daya Ram Pal ,  Pranav Jitendra Gangwar ,  Vikas Patel ,  Vishwadeepak Rama Pati Tripathi

IPC分类号： C07D207/33 ,  C07D207/333 ,  C07D207/325 ,  A61K31/402 ,  C07D207/32

摘要： The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.

公开(公告)号：US10233151B2

公开(公告)日：2019-03-19

申请号：US15319579

申请日：2015-06-17

申请人： Centre National de la Recherche Scientifique (CNRS)

发明人： Pascal Collin ,  Bernard Delpech ,  Joanna Bakala ,  Bogdan Iorga ,  Yves-Michel Frapart-Jannuad ,  Fabienne Peyrot ,  Franck Pelissier ,  Maria Conception Achab

IPC分类号： C07D403/10 ,  C07D207/333 ,  C07D207/325 ,  C07D405/10

摘要： The present invention relates to a 3-aryl-4 catechol-pyrrole-n-propanol compound and the derivatives thereof having General Formula (I), wherein:—R1 is an aryl group, particularly a phenyl, optionally substituted by one or more (C1-C2)alkyl groups, one or more halogens, one or more —OH, —CN or CF3 groups, or a combination of same, and—R2 is a (C1-C6)alkyl group, a hydroxy(C1-C6)alkyl group, a (C1-C4)alcoxy(C1-C6)alkyl group, or a pharmaceutically acceptable hydrate or solvate of same. The invention also relates to the methods for preparing said compound and derivatives, to the pharmaceutical compositions containing same, and to the use of same as a drug or in the form of a prodrug converted via dimerization, particularly via oxidative coupling in the presence of a superoxide anion, in the treatment of cancer and diseases related to excessive angiogenesis.

公开(公告)号：US20190031608A1

公开(公告)日：2019-01-31

申请号：US16121239

申请日：2018-09-04

申请人： UNIVERSITY OF NOTRE DAME DU LAC

发明人： William F. Schneider ,  Joan F. Brennecke ,  Edward J. Maginn ,  Elaine Mindrup ,  Burcu Gurkan ,  Erica Price ,  Brett Goodrich

IPC分类号： C07D207/32 ,  C07D209/08 ,  C07D207/33 ,  C07D207/323 ,  C07D233/58 ,  C07D207/325 ,  C07D207/46 ,  C07F9/54 ,  C07D231/12 ,  C07D207/34 ,  B01D53/14

摘要： Some embodiments described herein relate to ionic liquids comprising an anion of a heteraromatic compound such as optionally substituted pyrrolide, optionally substituted pyrazolide, optionally substituted indolide, optionally substituted phospholide, or optionally substituted imidazolide. Methods and devices for gas separation or gas absorption related to these ionic liquids are also described herein.

公开(公告)号：US20180297945A1

公开(公告)日：2018-10-18

申请号：US15947044

申请日：2018-04-06

申请人： Cadila Healthcare Limited

发明人： Shri Prakash Dhar Dwivedi ,  Ramesh Chandra Singh ,  Vikas Patel ,  Amar Rajendra Desai

IPC分类号： C07D207/333 ,  C07D207/325

摘要： The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium.

公开(公告)号：US09951008B2

公开(公告)日：2018-04-24

申请号：US13505730

申请日：2010-11-03

申请人： William F. Schneider ,  Joan F. Brennecke ,  Edward J. Maginn ,  Elaine Mindrup ,  Burcu Gurkan ,  Erica Price ,  Brett Goodrich

发明人： William F. Schneider ,  Joan F. Brennecke ,  Edward J. Maginn ,  Elaine Mindrup ,  Burcu Gurkan ,  Erica Price ,  Brett Goodrich

IPC分类号： B01D53/02 ,  C07D207/32 ,  B01D53/14 ,  C07D207/323 ,  C07D207/325 ,  C07D207/33 ,  C07D207/34 ,  C07D207/46 ,  C07D209/08 ,  C07D231/12 ,  C07D233/58 ,  C07F9/54

CPC分类号： C07D207/32 ,  B01D53/1456 ,  B01D53/1493 ,  B01D2252/30 ,  B01D2257/302 ,  B01D2257/404 ,  B01D2257/504 ,  B01D2258/0283 ,  C07D207/323 ,  C07D207/325 ,  C07D207/33 ,  C07D207/34 ,  C07D207/46 ,  C07D209/08 ,  C07D231/12 ,  C07D233/58 ,  C07F9/5407 ,  Y02C10/04 ,  Y02E20/326 ,  Y02P20/152

摘要： Some embodiments described herein relate to ionic liquids comprising an anion of a heteraromatic compound such as optionally substituted pyrrolide, optionally substituted pyrazolide, optionally substituted indolide, optionally substituted phospholide, or optionally substituted imidazolide. Methods and devices for gas separation or gas absorption related to these ionic liquids are also described herein.

公开(公告)号：US09845317B2

公开(公告)日：2017-12-19

申请号：US15142418

申请日：2016-04-29

申请人： The Board of Trustees of the University of Illinois

发明人： Martin D. Burke ,  David M. Knapp ,  Eric P. Gillis

IPC分类号： C07F5/02 ,  C07F5/04 ,  C07D413/04 ,  C07C1/32 ,  C07C41/30 ,  C07D207/325 ,  C07D213/73 ,  C07D241/42 ,  C07D263/56 ,  C07D307/42 ,  C07D401/04 ,  C07D405/12 ,  C07D409/04 ,  C07B61/00 ,  C07D207/333 ,  C07D209/12 ,  C07D307/36 ,  C07D307/80 ,  C07D333/16 ,  C07D405/04 ,  C07D207/34 ,  C07D209/30 ,  C07D213/16 ,  C07D213/50 ,  C07D213/57

CPC分类号： C07D413/04 ,  C07B61/00 ,  C07C1/321 ,  C07C41/30 ,  C07C2527/173 ,  C07C2531/12 ,  C07C2531/24 ,  C07C2601/02 ,  C07D207/325 ,  C07D207/333 ,  C07D207/34 ,  C07D209/12 ,  C07D209/30 ,  C07D213/16 ,  C07D213/50 ,  C07D213/57 ,  C07D213/73 ,  C07D241/42 ,  C07D263/56 ,  C07D307/36 ,  C07D307/42 ,  C07D307/80 ,  C07D333/16 ,  C07D401/04 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  Y02P20/55 ,  C07C15/46 ,  C07C15/58 ,  C07C13/28 ,  C07C43/2055

摘要： A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture: R1—B-T  (I); where R1 represents an organic group, T represents a conformationally rigid protecting group, and B represents boron having sp3 hybridization. When unprotected, the corresponding organoboronic acid is unstable by the boronic acid neat stability test. The reaction mixture further includes a base having a pKB of at least 1 and a palladium catalyst. The method further includes forming a cross-coupled product in the reaction mixture.

公开(公告)号：US09714219B2

公开(公告)日：2017-07-25

申请号：US14917589

申请日：2015-06-10

申请人： Novartis Tiergesundheit AG

发明人： Noelle Gauvry ,  Francois Pautrat ,  Jean-Luc Perret ,  Chouaib Tahtaoui

IPC分类号： C07C311/09 ,  A01N41/06 ,  A01N55/00 ,  C07D207/325 ,  C07D213/643 ,  C07F7/08 ,  C07C311/08 ,  A01N43/36 ,  A01N43/40 ,  A01N43/54 ,  A01N43/78 ,  C07D239/34 ,  C07D207/335 ,  C07D277/66 ,  A01N43/84 ,  C07D295/096 ,  C07D295/155

CPC分类号： C07C311/08 ,  A01N41/06 ,  A01N43/36 ,  A01N43/40 ,  A01N43/54 ,  A01N43/78 ,  A01N43/84 ,  A01N55/00 ,  C07D207/325 ,  C07D207/335 ,  C07D213/643 ,  C07D239/34 ,  C07D277/66 ,  C07D295/096 ,  C07D295/155 ,  C07F7/081

摘要： The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.